35 results on '"Kotsianidis I"'
Search Results
2. Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: NOVEL PREDICTIVE INDICATORS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS (HR-MDS) TREATED WITH 5-AZACYTIDINE: CUMULATIVE DATA FROM THE HELLENIC MDS STUDY GROUP
3. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
4. CURRENT CARDIOVASCULAR DISEASE (CVD) RISK PREDICTION MODELS ARE NOT APPLICABLE IN MDS PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE OBSERVATIONAL SINGLE-CENTRE COHORT STUDY
5. Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINE DEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME
6. P102 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: NOVEL PREDICTIVE INDICATORS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS (HR-MDS) TREATED WITH 5-AZACYTIDINE: CUMULATIVE DATA FROM THE HELLENIC MDS STUDY GROUP
7. P101 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINE DEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME
8. P082 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: SYSTEMATIC ANALYSIS OF T LYMPHOCYTES IN MYELOID NEOPLASMS
9. P011 - Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
10. O05 - CURRENT CARDIOVASCULAR DISEASE (CVD) RISK PREDICTION MODELS ARE NOT APPLICABLE IN MDS PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE OBSERVATIONAL SINGLE-CENTRE COHORT STUDY
11. Lenalidomide Induces Responses in Patients with MDS-DEL(5)Q Alone, or with One Additional Abnormality, Irrespective of Who Classification and Prognostic Categorization
12. Primary Resistance to Azacytidine in MDS: Preliminary Data on the Potential Role of HIF-1A Expression – the Hellenic MDS Study Group
13. Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents
14. 283 AZACYTIDINE UPREGULATES PERFORIN EXPRESSION IN CYTOTOXIC T AND NATURAL KILLER CELLS OF RESPONDING PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)
15. 123 - Lenalidomide Induces Responses in Patients with MDS-DEL(5)Q Alone, or with One Additional Abnormality, Irrespective of Who Classification and Prognostic Categorization
16. 113 - Primary Resistance to Azacytidine in MDS: Preliminary Data on the Potential Role of HIF-1A Expression – the Hellenic MDS Study Group
17. 49 - Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents
18. P-244 Distinct epigenetic modulation of signal transducer and activator of transcription (STAT) signaling in FOXP3+ T regulatory cells of CMML-2 patients
19. Long-term bone marrow cultures (LTBMC) from essential thrombocythemia (ET) patients with or without JAK2617V>F mutation
20. 319 Response to treatment with erythropoietin in patients with MDS highly predicts low risk of evolution to AML and longer survival
21. 67 Response to ESA treatment in patients with MDS: Determination of a predictive score, from a retrospective analysis of 669 patients
22. 294 Prognostic significance of beta 2 microglobulin in survival and transformation to acute myelogenous leukemia in patients with myelodysplastic syndrome
23. 311 STAT signaling alterations in leukemic progenitors can predict the response of myelodysplastic syndrome (MDS) patients to azacytidine
24. P050 Evidence for a role of CD4+CD25high Foxp3+ regulatory T-cells in the pathogenesis of myelodysplastic syndromes (MDS)
25. Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis.
26. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database.
27. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
28. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.
29. Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-Myeloproliferative neoplasms.
30. Surface antigen expression in CLL: a new member among the mnesteres for the prognosis of bad risk disease.
31. Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience.
32. Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment.
33. Hypomethylating therapy and autoimmunity in MDS: an enigmatic relationship.
34. Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms.
35. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.